Emimen Co. Ltd. (9237.T)
Osaka, JP
Emimen Co., Ltd. provides senior home introduction services in Japan. The company offers information about senior homes; support services for moving into senior homes and information on senior homes; senior home consulting services; and care prime community site management services. Emimen Co., Ltd. was incorporated in 2010 and is headquartered in Osaka, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.29% | -3.40% | -26.75% | -40.47% | -46.39% | -40.88% | -49.23% | -31.82% | -31.82% | -31.82% | -31.82% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Real Estate - Development: +9.7%+43.9% ★ Q2'26: +50.5% (vs Q2'25)
-
EPS growth Real Estate - Development: +20.5%-50.4% Q2'26: +480.5% (vs Q2'25)
-
FCF margin FCF growth · Real Estate - Development: +16.2%+4.5% Q2'26: +1.3% (vs Q2'25)
-
EBIT margin Real Estate - Development: +19.8%+6.1% Q2'26: +21.5% (vs Q2'25)
-
ROIC Real Estate - Development: +3.2%+31.6% ★ Q2'26: +100.4% (vs Q2'25)
-
Share dilution Real Estate - Development: +0.0%+0.6% Q2'26: -0.9% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Real Estate - Development: 1.93×1.02× ★ Q2'26: 0.57× (vs Q2'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Oct 2024 actual |
Oct 2025 actual |
Oct 2026 1 Rev. Ana. 1 EPS Ana. |
Oct 2027 1 Rev. Ana. 1 EPS Ana. |
Oct 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
1.30B
est: 1.28B (+2.1%)
|
1.87B
est: 2.01B (-6.9%)
|
2.53B
2.53B – 2.53B
+25.8% YoY
|
3.35B
3.35B – 3.35B
+32.3% YoY
|
4.68B
4.68B – 4.68B
+39.8% YoY
|
| EBITDA |
222.17M
est: 64.91M (+242.3%)
|
123.22M
est: 102.38M (+20.4%)
|
128.75M
128.75M – 128.75M
+25.8% YoY
|
170.29M
170.29M – 170.29M
+32.3% YoY
|
238.05M
238.05M – 238.05M
+39.8% YoY
|
| EBIT |
216.81M
est: 59.18M (+266.3%)
|
113.48M
est: 93.34M (+21.6%)
|
117.39M
117.39M – 117.39M
+25.8% YoY
|
155.26M
155.26M – 155.26M
+32.3% YoY
|
217.04M
217.04M – 217.04M
+39.8% YoY
|
| Net Income |
179.65M
est: 205.39M (-12.5%)
|
89.67M
est: 237.29M (-62.2%)
|
160.53M
160.53M – 160.53M
-32.4% YoY
|
257.67M
257.67M – 257.67M
+60.5% YoY
|
338.76M
338.76M – 338.76M
+31.5% YoY
|
| SGA |
699.87M
est: 752.25M (-7.0%)
|
822.37M
est: 1.19B (-30.7%)
|
1.49B
1.49B – 1.49B
+25.8% YoY
|
1.97B
1.97B – 1.97B
+32.3% YoY
|
2.76B
2.76B – 2.76B
+39.8% YoY
|
| EPS |
44.64
est: 49.90 (-10.5%)
|
22.12
est: 57.65 (-61.6%)
|
39.00
39.00 – 39.00
-32.4% YoY
|
62.60
62.60 – 62.60
+60.5% YoY
|
82.30
82.30 – 82.30
+31.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-10 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-09 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-03 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-02 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hiroshi Kinoshita | MD & Director | — | male |
| Masaharu Kamata | CFO & Director | — | — |
| Masayuki Emine | President & Chairman | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9237.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
